Darren Mikesell, DO
Family Medicine · Laramie, WYNPI 1275733180
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $769 and has fallen 82.4% since, to $136 in 2025. Among family medicine clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$418
- Novo Nordisk$211
- GSK$176
- Lilly USA, LLC$165
- Abbott$132
- Vanda Pharmaceuticals Inc.$116
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,24599%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $418 |
| Novo Nordisk | 12 | $211 |
| GSK | 10 | $176 |
| Lilly USA, LLC | 11 | $165 |
| Abbott | 6 | $132 |
| Vanda Pharmaceuticals Inc. | 4 | $116 |
| AstraZeneca | 7 | $112 |
| Merck | 6 | $97 |
| Amgen | 6 | $93 |
| Johnson & Johnson | 2 | $80 |
| Amarin Pharma, Inc. | 3 | $69 |
| Medtronic(2 entities) | 3 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Boehringer Ingelheim | 1 | $50 |
| Astellas Pharma US Inc | 2 | $46 |
| Lundbeck LLC | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Pfizer | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Exact Sciences | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Alkermes, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Optinose US, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Neotract Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Pacira Therapeutics, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$2,274 in reported general payments places this provider in the 90th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $126,693 |
| EliquisApixaban | 203 | $122,081 |
| JardianceEmpagliflozin | 81 | $77,280 |
| XareltoRivaroxaban | 95 | $74,204 |
| MounjaroTirzepatide | 41 | $60,385 |
| MyrbetriqMirabegron | 50 | $46,138 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $29,932 |
| JanuviaSitagliptin Phosphate | 16 | $25,998 |
| FarxigaDapagliflozin Propanediol | 39 | $25,015 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $18,217 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $11,626 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $11,039 |
| Atorvastatin Calcium | 636 | $9,373 |
| OxycontinOxycodone Hcl | 12 | $6,821 |
| Aripiprazole | 34 | $5,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $211 | $126,69398 claims |
| PfizerEliquis | $31 | $122,081203 claims |
| Boehringer IngelheimJardiance | $50 | $77,28081 claims |
| Johnson & JohnsonXarelto | $80 | $74,20495 claims |
| Lilly USA, LLCMounjaro | $165 | $60,38541 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $46,13850 claims |
| MerckJanuvia, Belsomra, Dulera | $97 | $36,62944 claims |
| GSKBreo Ellipta | $176 | $29,93265 claims |
| AstraZenecaFarxiga | $112 | $25,01539 claims |
| Eisai Inc.Dayvigo | $17 | $4,89915 claims |
| AbbVieSynthroid | $418 | $3,30954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Laramie
- John HaeberleLaramie$1K
- Andrea HabelLaramie$1K
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Jonathon MedinaCheyenne$6K
- Carol FischerCheyenne$6K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.